1. Pink Sheet
  2. >>Pathways & Standards
  3. >>Approval Standards

US FDA ‘Thinking Deeply’ On ‘Digital Twins’ As Placebo Control, But OCE Not Quite Ready To Embrace It

 
• By Kate Rawson

Oncology staff also said more work is needed before patient registries can be used as an external control in clinical trials, but they strongly encouraged continued investment.

digital twins
Oncology trial control arms might need to stay IRL in the near term. (Nielsen Hobbs; the Pink Sheet | Shutterstock images)

The Oncology Center of Excellence says it is open to considering the use of artificial intelligence-powered “digital twins” as an alternative to human placebos in clinical trials, but OCE is not quite ready to fully endorse its use while the US Food & Drug Administration is still considering its overall regulatory policy.

Key Takeaways
  • “Digital twins” – creating an AI model of a patient to predict behavior – remain under consideration for control arms in oncology trials, FDA says.


“The use of digital twins is something that FDA is still thinking very deeply about at a policy level,” Center...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approval Standards

More from Geography

ACIP Upheaval Leaves Merck & Co. In A Lurch

 
• By Jessica Merrill and Bridget Silverman

Merck’s newly approved Enflonsia for RSV is one of the products expected to be recommended for use by the CDC Advisory Committee on Immunization Practices later this month.

‘Sex Pill For Women’: Sprout CEO’s Addyi Instagram Post Draws US FDA Warning Letter

 
• By Sue Sutter

Cindy Eckert’s social media post with a People.com story failed to include any risk information, made misleading representations about benefits and omitted material information about the indication, said the agency, which flagged similar concerns about an Addyi radio ad five years ago.

US FDA Chief Counsel Position Awaits HHS General Counsel Confirmation

 
• By Sue Sutter

Robert Foster, HHS deputy general counsel and chief counsel for food, research and drugs, is temporarily heading the Office of Chief Counsel, but a permanent appointee is expected after Michael Stuart's confirmation as HHS general counsel.